TABLE 2.
Biodistribution Data of 89Zr-DFO-J591, Administered Intravenously to Mice Bearing Subcutaneous PC-3 Tumors (3–4 µg of mAb)
| Organ | 48 h (n = 4) | 96 h (n = 3) |
|---|---|---|
| Blood | 19.0 ± 1.1 | 13.0 ± 1.8 |
| Tumor | 15.6 ± 2.1 | 24.0 ± 2.6 |
| Heart | 6.8 ± 0.1 | 4.3 ± 0.9 |
| Lung | 12.6 ± 1.9 | 7.0 ± 2.3 |
| Liver | 12.4 ± 0.9 | 11.0 ± 1.6 |
| Spleen | 10.2 ± 2.0 | 7.2 ± 0.7 |
| Kidney | 10.5 ± 0.9 | 6.9 ± 1.6 |
| Muscle | 1.5 ± 0.4 | 0.9 ± 0.2 |
| Bone | 4.3 ± 0.6 | 5.1 ± 0.5 |
| Tumor/blood | 0.8 ± 0.1 | 1.8 ± 0.3 |
| Tumor/heart | 2.3 ± 0.3 | 5.6 ± 1.4 |
| Tumor/lung | 1.2 ± 0.3 | 3.4 ± 1.2 |
| Tumor/liver | 1.3 ± 0.2 | 2.2 ± 0.4 |
| Tumor/spleen | 1.5 ± 0.4 | 3.4 ± 0.5 |
| Tumor/kidney | 1.5 ± 0.2 | 3.5 ± 0.9 |
| Tumor/muscle | 10.4 ± 3.3 | 25.4 ± 5.8 |
| Tumor/bone | 3.6 ± 0.7 | 4.7 ± 0.7 |
Complete biodistribution data are presented in Supplemental Table 7. Data are expressed as mean %ID/g ± SD. Errors for tumor-to-tissue ratios are calculated as geometric mean of SD. PC-3 tumors: PSMA-negative, 70–90 mm3.